ATE529511T1 - Immunstimulatorische eigenschaften von verbindungen auf oligonukleotid-basis mit modifizierten immunstimulatorischen dinukleotiden - Google Patents

Immunstimulatorische eigenschaften von verbindungen auf oligonukleotid-basis mit modifizierten immunstimulatorischen dinukleotiden

Info

Publication number
ATE529511T1
ATE529511T1 AT05851907T AT05851907T ATE529511T1 AT E529511 T1 ATE529511 T1 AT E529511T1 AT 05851907 T AT05851907 T AT 05851907T AT 05851907 T AT05851907 T AT 05851907T AT E529511 T1 ATE529511 T1 AT E529511T1
Authority
AT
Austria
Prior art keywords
stimulative
immuno
oligonucleotides
immunostimulatory
oligonucleotide
Prior art date
Application number
AT05851907T
Other languages
English (en)
Inventor
Sudhir Agrawal
Dong Yu
Ekambar Kandimalla
Original Assignee
Idera Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idera Pharmaceuticals filed Critical Idera Pharmaceuticals
Application granted granted Critical
Publication of ATE529511T1 publication Critical patent/ATE529511T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/336—Modified G

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05851907T 2005-11-07 2005-11-07 Immunstimulatorische eigenschaften von verbindungen auf oligonukleotid-basis mit modifizierten immunstimulatorischen dinukleotiden ATE529511T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2005/042068 WO2007055704A2 (en) 2005-11-07 2005-11-07 Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides

Publications (1)

Publication Number Publication Date
ATE529511T1 true ATE529511T1 (de) 2011-11-15

Family

ID=38023711

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05851907T ATE529511T1 (de) 2005-11-07 2005-11-07 Immunstimulatorische eigenschaften von verbindungen auf oligonukleotid-basis mit modifizierten immunstimulatorischen dinukleotiden

Country Status (8)

Country Link
EP (3) EP2371956A3 (de)
JP (1) JP5184366B2 (de)
CN (1) CN101351228A (de)
AT (1) ATE529511T1 (de)
AU (1) AU2005338035B2 (de)
CA (1) CA2628306C (de)
MX (1) MX2008006005A (de)
WO (1) WO2007055704A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7470674B2 (en) * 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
EP2357231A2 (de) * 2007-07-09 2011-08-17 Idera Pharmaceuticals, Inc. Stabilisierte immunmodulatorische RNA (SIMRA)-Verbindungen
ES2539353T3 (es) * 2007-08-01 2015-06-30 Idera Pharmaceuticals, Inc. Nuevos agonistas sintéticos de TLR9
EP3164113B1 (de) 2014-06-04 2019-03-27 Exicure, Inc. Multivalente freisetzung von immunmodulatoren durch liposomale sphärische nukleinsäuren für prophylaktische oder therapeutische anwendungen
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
JP7186094B2 (ja) 2016-05-06 2022-12-08 イグジキュア オペレーティング カンパニー インターロイキン１７受容体ｍＲＮＡの特異的ノックダウンのためのアンチセンスオリゴヌクレオチド（ＡＳＯ）を提示するリポソーム系球状核酸（ＳＮＡ）構築物
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149798A (en) 1989-04-06 1992-09-22 Worcester Foundation For Experimental Biology Process for synthesizing oligonucleotides and their analogs adaptable to large scale syntheses
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US5652355A (en) 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
TW244371B (de) 1992-07-23 1995-04-01 Tri Clover Inc
US6346614B1 (en) 1992-07-23 2002-02-12 Hybridon, Inc. Hybrid oligonucleotide phosphorothioates
US5912332A (en) 1996-07-26 1999-06-15 Hybridon, Inc. Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
EP2314693A3 (de) 1999-08-13 2012-11-28 Idera Pharmaceuticals, Inc. Modulierung der durch CpG-oligonukleotide verursachte Immunstimulierung durch positionsbedingte Veränderung von Nukleosiden
EP1252307B1 (de) 2000-01-26 2008-01-02 Idera Pharmaceuticals, Inc. Modulierung der durch cpg-oligonukleotide verursachte immunstimulierung durch positionsbedingte veränderung von nukleosiden
WO2003035836A2 (en) * 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
AU2004206820B2 (en) * 2003-01-16 2010-06-10 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
US7427405B2 (en) * 2004-06-15 2008-09-23 Idera Pharmaceuticals, Inc. Immunostimulatory oligonucleotide multimers

Also Published As

Publication number Publication date
AU2005338035B2 (en) 2012-06-07
EP2371956A2 (de) 2011-10-05
CA2628306C (en) 2014-06-17
EP2402442A2 (de) 2012-01-04
EP2402442A3 (de) 2012-03-28
EP1942945B1 (de) 2011-10-19
EP2371956A3 (de) 2012-01-04
AU2005338035A1 (en) 2007-05-18
EP1942945A2 (de) 2008-07-16
JP5184366B2 (ja) 2013-04-17
WO2007055704A3 (en) 2007-12-06
EP2402442B1 (de) 2013-07-31
MX2008006005A (es) 2008-10-01
CN101351228A (zh) 2009-01-21
JP2009514527A (ja) 2009-04-09
CA2628306A1 (en) 2007-05-18
WO2007055704A2 (en) 2007-05-18
EP1942945A4 (de) 2009-01-21

Similar Documents

Publication Publication Date Title
KR20050100375A (en) Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
WO2003057822A3 (en) Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
CY1108870T1 (el) Αντιπαραλληλα ολιγονουκλεοτιδια (odn) κατα της smad7 και χρησεις στον ιατρικο τομεα τους
TW200738877A (en) Immunostimulatory oligoribonucleotides
DE50006758D1 (de) Kovalent geschlossenes nukleinsäuremolekül zur immunstimulation
NO20081884L (no) Modulasjon av glukagonreseptorekspresjon
NO20081883L (no) Modulasjon av glukokortikoidreseptorekspresjon
TNSN07150A1 (en) Semi-soft c-class immunostimulatory oligonucleotides
WO2006116458A3 (en) Modified oligoribonucleotide analogs with enhances immunostimulatory activity
NO20082448L (no) Kombinasjoner av angiopoietin-2 antagonister og VEGF-A, KDR og/eller FLT1 antagonist for behandling av cancer
WO2006089001A3 (en) Lentiviral vectors and their use
ATE536376T1 (de) Humanes bindungsmolekül gegen cd1a
MX2009008139A (es) Derivdos de 2-5a y su uso como agentes anti-cancer, antivirales y anti-parasitos.
TW200507874A (en) Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
WO2006104913A3 (en) USE OF ANTI-TNF OR ANTI-ILl RNAI TO SUPPRESS PRO- INFLAMMATORY CYTOKINE ACTIONS LOCALLY TO TREAT PAIN
MX2009012482A (es) Oligonucleotidos de clase a con potencia inmunoestimuladora.
CA3029451C (en) Discontinuous oligonucleotide ligands
MX2009012317A (es) Tratamiento y prevencion de influenza.
EP1942945A4 (de) Immunstimulatorische eigenschaften von verbindungen auf oligonukleotid-basis mit modifizierten immunstimulatorischen dinukleotiden
WO2005014814A3 (en) 5’-and 3’-capped aptamers and uses therefor
ES2193958T3 (es) Inmunoadsorbentes para el tratamiento de la septicemia.
WO2009027978A8 (en) NUCLEIC ACID SEQUENCES COMPRISING NF-ϰB BINDING SITE WITHIN O(6)-METHYLGUANINE-DNA-METHYLTRANSFERASE (MGMT) PROMOTER REGION AND USES THEREOF FOR THE TREATMENT OF CANCER AND IMMUNE-RELATED DISORDERS
EP1648910A4 (de) Antisense-modulation der expression von stearoyl coa desaturase
WO2007084237A3 (en) Novel synthetic agonists of toll-like receptors containing cg dinucleotide modifications
GB0300718D0 (en) Proteins

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties